Table 5.
Multivariate analysis of the effect of HLA-C matching score after dUCB transplantation considering the predominant cord blood unit.
| N | HR (95% Confidence interval) | P-value | |
|---|---|---|---|
| Disease-Free Survival | |||
| HLA-C match score | |||
| 2/2* | 117 | 1.0 | |
| 1/2 | 232 | 1.0 (0.8–1.4) | 0.83 |
| 0/2 | 67 | 1.1 (0.8–1.7) | 0.52 |
| HLA Match -A, -B, and -DRB1 | |||
| 5–6/6* | 154 | 1.0 | |
| 4/6 | 184 | 0.9 (0.6–1.3) | 0.72 |
| 2–3/6 | 78 | 1.0 (0.7–1.5) | 0.91 |
| Risk | |||
| Standard* | 268 | 1.0 | |
| High | 148 | 1.3 (1.0–1.7) | 0.08 |
| CMV | |||
| No* | 175 | 1.0 | |
| Yes | 241 | 1.4 (1.1–1.8) | 0.01 |
| Relapse | |||
| HLA-C match score | |||
| 2/2* | 117 | 1.0 | |
| ½ | 232 | 0.9 (0.6–1.3) | 0.44 |
| 0/2 | 67 | 1.0 (0.6–1.7) | 0.93 |
| HLA Match -A, -B, and -DRB1 | |||
| 5–6/6* | 154 | 1.0 | |
| 4/6 | 184 | 0.9 (0.6–1.4) | 0.60 |
| 2–3/6 | 78 | 0.9 (0.5–1.6) | 0.73 |
| Conditioning | |||
| MA* | 136 | 1.0 | |
| RIC | 280 | 2.6 (1.6–4.2) | <0.01 |
| Grade II–IV AGVHD | |||
| No* | 217 | 1.0 | |
| Yes | 199 | 0.7 (0.5–1.0) | 0.06 |
| Non-Relapse Mortality | |||
| HLA-C match score | |||
| 2/2* | 117 | 1.0 | |
| 1/2 | 232 | 1.4 (0.8–2.3) | 0.20 |
| 0/2 | 67 | 1.4 (0.7–2.7) | 0.31 |
| HLA Match -A, -B, and -DRB1 | |||
| 5–6/6* | 154 | 1.0 | |
| 4/6 | 184 | 0.9 (0.6–1.5) | 0.72 |
| 2–3/6 | 78 | 1.2 (0.7–2.0) | 0.61 |
| Conditioning | |||
| MA* | 136 | 1.0 | |
| RIC | 280 | 0.5 (0.3–0.7) | <0.01 |
| Disease Risk | |||
| Standard | 268 | 1.0 | |
| High | 148 | 1.7 (1.1–2.5) | 0.01 |
| CMV | |||
| Negative* | 175 | 1.0 | |
| Positive | 241 | 1.5 (1.0–2.2) | 0.07 |
HLA, human leukocyte antigen; dUCB, double umbilical cord blood; N, number of patients; CI, confidence interval; GVHD, graft-vs-host disease; CMV cytomegalovirus.
*
Reference group
£
Stratified by transplant center